Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
在接受积极治疗的实体瘤患者中,接种第三剂BNT162b2抗SARS-CoV-2疫苗后的免疫原性和安全性:一项前瞻性队列研究
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100458
Lasagna, A; Bergami, F; Lilleri, D; Percivalle, E; Quaccini, M; Alessio, N; Comolli, G; Sarasini, A; Sammartino, J C; Ferrari, A; Arena, F; Secondino, S; Cicognini, D; Schiavo, R; Lo Cascio, G; Cavanna, L; Baldanti, F; Pedrazzoli, P; Cassaniti, I